Ed Sheeran, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
GLP-1 medication and metabolic health image for Ed Sheeran, Maintenance, and What Happens If You Stop

The Public Record: What Ed Sheeran Has Actually Said

Ed Sheeran's physical transformation became a visible topic around 2023 and 2024, coinciding with a period of heavy touring and public appearances tied to his Mathematics Tour. In interviews, Sheeran has attributed his weight changes to lifestyle factors. He has spoken openly about cutting back on alcohol, increasing physical activity, and adjusting his diet during touring cycles.

He has not publicly confirmed using semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or any other GLP-1 receptor agonist. No credible reporting from outlets like People, The Guardian, or BBC has presented evidence of GLP-1 use. The speculation exists almost entirely on social media and in tabloid commentary, where any male celebrity who loses weight during the post-2022 GLP-1 boom becomes a candidate for rumors.

The HealthRX Medical Team emphasizes this distinction: public speculation is not a medical record. Sheeran's stated explanation (diet and exercise) is the only account on the record.

At a glance

  • Confirmed GLP-1 use: None. Ed Sheeran has not publicly disclosed using any GLP-1 medication.
  • Stated explanation: Exercise, dietary changes, reduced alcohol intake during touring.
  • Source of speculation: Visible weight loss timing overlapped with the broader cultural surge of GLP-1 prescriptions (2022-2025).
  • Clinical focus of this page: What happens when someone discontinues a GLP-1 agonist, and what the research says about maintaining weight loss long-term, whether pharmacologically assisted or not.

Why the Speculation Follows a Pattern

Sheeran's situation fits a recognizable template. A male public figure loses noticeable weight over 6 to 12 months. The timeline overlaps with the explosion of GLP-1 prescriptions. Observers assume a pharmaceutical explanation because the results appear rapid.

This pattern has repeated with dozens of male celebrities since semaglutide received FDA approval for chronic weight management in June 2021 (FDA approval letter, Wegovy). The cultural assumption has shifted: weight loss is now "guilty until proven innocent" in the court of public opinion. The HealthRX Medical Team notes that this assumption ignores the well-documented capacity of sustained caloric deficits and increased activity to produce meaningful results, particularly in individuals who previously maintained sedentary touring lifestyles with high caloric intake.

The Clinical Question: What Happens When You Stop a GLP-1?

Whether or not Sheeran has ever used a GLP-1 agonist, the discontinuation question is the one his public story raises by proxy. Millions of patients prescribed these drugs face the same concern: if I stop, do I regain the weight?

The short answer from clinical trials is yes, most people do.

The STEP 1 Extension Data

The landmark STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, followed participants for one year after withdrawal of semaglutide 2.4 mg. Participants regained approximately two-thirds of their prior weight loss within 12 months of stopping the drug. Cardiometabolic improvements in blood pressure, lipid levels, and HbA1c also reversed proportionally (Wilding et al., 2022).

The SURMOUNT-4 Trial (Tirzepatide)

The SURMOUNT-4 trial, published in JAMA in 2024, examined tirzepatide discontinuation in a randomized withdrawal design. Participants who switched from tirzepatide to placebo after 36 weeks regained roughly half of the weight they had lost, while those who continued treatment maintained or extended their losses (Aronne et al., 2024). The results confirmed a consistent pattern: GLP-1 receptor agonists suppress appetite through central and peripheral mechanisms, and removing that pharmacologic signal restores prior hunger and metabolic set-point pressures.

Why Weight Regain Happens: The Biology

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, slowing gastric emptying, reducing appetite signaling in the hypothalamus, and improving insulin sensitivity (Drucker, 2018). These effects are dose-dependent and drug-dependent. When the medication is withdrawn, the biological drivers of weight regain reassert themselves:

  • Appetite restoration. Hunger returns to pre-treatment levels, often within weeks of the last dose.
  • Metabolic adaptation. Resting metabolic rate drops in proportion to weight lost, a phenomenon well-characterized independent of GLP-1 use (Rosenbaum & Leibel, 2010).
  • Hormonal rebound. Ghrelin and other orexigenic signals increase as the body attempts to defend its prior weight set-point.

The HealthRX Medical Team stresses that this is not a failure of willpower. It is a predictable physiological response. Obesity is classified by the American Medical Association and the Endocrine Society as a chronic disease requiring sustained management (Endocrine Society clinical practice guidelines).

Maintenance Without the Drug: What the Evidence Supports

For anyone who loses weight (by any method) and wants to maintain it, the research points to a handful of strategies with real evidence behind them.

Sustained Physical Activity

The National Weight Control Registry, which tracks individuals who have maintained >13 kg of weight loss for more than a year, consistently identifies high levels of physical activity as the strongest predictor of maintenance. Registry members report an average of 60 to 90 minutes of moderate-intensity exercise per day (Wing & Phelan, 2005).

Sheeran's own statements about increased exercise during touring align with this evidence, regardless of any pharmacologic question.

Dietary Monitoring

Self-monitoring of dietary intake, whether through calorie counting, food logging, or structured meal planning, remains one of the most replicated predictors of long-term weight maintenance in behavioral research (Burke et al., 2011).

Reduced Alcohol Intake

Sheeran has publicly discussed reducing alcohol consumption. Alcohol contributes caloric load (7 kcal/g), impairs fat oxidation, and increases impulsive eating behavior. Reducing intake is independently associated with improved weight management outcomes, a point the HealthRX Medical Team considers underappreciated in popular weight-loss discourse.

Pharmacologic Maintenance (If Applicable)

For patients who have used GLP-1 agonists, the emerging clinical consensus supports long-term or indefinite use to maintain results, similar to the treatment model for hypertension or type 2 diabetes. The SELECT trial demonstrated cardiovascular benefit from sustained semaglutide use in patients with established cardiovascular disease and obesity, independent of diabetes status (Lincoff et al., 2023). This trial, published in The New England Journal of Medicine, shifted the risk-benefit conversation: for high-risk patients, staying on therapy may reduce major adverse cardiovascular events by 20%.

Dose stepping (reducing from a therapeutic dose to a lower maintenance dose) is an area of active clinical investigation. Some clinicians use lower doses to balance side effects against weight maintenance, though no completed Phase III trial has validated a specific step-down protocol as of mid-2026.

The HealthRX Medical Team Take

Ed Sheeran's weight loss is publicly attributed to exercise and dietary changes. That explanation is consistent with established clinical evidence and should be taken at face value absent any contradicting disclosure.

The broader lesson from the speculation around him is about the cultural moment, not about Sheeran himself. GLP-1 receptor agonists have become so widespread that visible weight loss in any public figure now triggers assumptions of pharmaceutical use. This speaks to how rapidly these medications have reshaped public expectations about what weight loss "looks like."

From a clinical standpoint, the HealthRX Medical Team highlights three things this story puts in relief:

  1. GLP-1 discontinuation carries a real and quantified risk of weight regain. The STEP 1 extension and SURMOUNT-4 data are clear on this. Patients considering stopping should work with their prescribing physician to develop a structured maintenance plan.
  2. Behavioral interventions remain the foundation. Whether someone uses pharmacotherapy or not, sustained physical activity, dietary monitoring, and reduced alcohol intake are the evidence-backed pillars of weight maintenance.
  3. Speculation is not a substitute for disclosure. Clinicians, journalists, and the public should resist the impulse to diagnose medication use based on appearance. Weight loss has multiple pathways, and attributing it to drugs without evidence undermines both the individual and the complexity of obesity treatment.

Frequently asked questions

›
›
›
›
›

References

  • Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022. PubMed
  • Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024. JAMA
  • Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018. PubMed
  • Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes. 2010. PubMed
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023. PubMed
  • Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005. PubMed
  • Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: a systematic review. J Am Diet Assoc. 2011. PubMed
  • FDA. Wegovy (semaglutide) approval letter. 2021. FDA
  • Endocrine Society. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Endocrine.org